Alyce Arnick Lichaa

Alyce Arnick Lichaa has over 16 years of experience in finance and operations. In 2004, they began their career at EWT, LLC (n.k.a. Virtu Financial) as a Settlement Operations / Securities Lending Analyst. Alyce Arnick then moved to Shell Trading US CO in 2006 as an Analyst, Trading Operations. In 2008, they were a Summer Associate, Global Compensation Operations (Customer Solutions Finance) at Cisco. In 2009, they joined McKesson as part of the Finance Rotational Development Program. In 2010, they were a Senior Analyst, Clinical Business Operations at FibroGen, Inc. From 2012 to 2017, they held various roles at McKesson, including Senior Manager, Business Operations and Manager, Strategic Sourcing (Product Management Analytics). In 2017, they were a Consultant at RGP. From 2018 to 2020, they were at Allogene Therapeutics, where they held the role of Senior Manager, FP&A. During this time, they were the sole FP&A employee from company start-up through IPO, and then one of a two-person FP&A team responsible for the forecasting and financial reporting of the rapidly-growing public company. In 2020, they moved to Alector as Director of FP&A and Associate Director, FP&A. Currently, they are the Senior Director Finance, Head of FP&A at ReCode Therapeutics.

Alyce Arnick Lichaa received their MBA from the Texas McCombs School of Business in 2009. Alyce Arnick earned their Bachelor of Arts (B.A.) in English Language and Literature from Colorado State University in 2002. Alyce Arnick also studied Latin Language and Literature at Loyola University Chicago.